New hope for ALS patients: experimental drug IFB-088 tested in trial
Disease control
Completed
This phase 2 trial tested whether adding IFB-088 to standard riluzole treatment is safe and effective for people with bulbar-onset ALS (a form that first affects speech and swallowing). 51 participants received either IFB-088 plus riluzole or a placebo plus riluzole for 6 months.…
Phase: PHASE2 • Sponsor: InFlectis BioScience • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC